DRUG RELEASE AND PHARMACOKINETIC PROPERTIES OF LIPOSOMAL DB-67
作者： Yali Liang
DOI:
关键词:
摘要: OF THESIS DRUG RELEASE AND PHARMACOKINETIC PROPERTIES LIPOSOMAL DB-67 Sterically stabilized liposomes with saturated lipid as the major component (DSPC:m-PEGDSPE 95:5 mole%) were applied in delivery. The drug retention vitro and pharmacokinetic properties vivo investigated. Liposomal was cleared faster from circulation larger (~180 nm) than smaller ones (~120 nm), even though retained longer size vitro. clearance increased when cholesterol present liposomal composition (40 mole %). It can be attributable to release containing compared without cholesterol. Cholesterol free particle chosen optimal formulation. In addition, high doses led lower of because carriers longer. Liposomes taken up by liver spleen a greater extent ones. But content dose did not alter tissue uptake liposomes. area under plasma concentration-time curve (AUC) for 40-fold higher that non-liposomal DB-67.
参考文章(69)
Asymptotic Theory for Parametric Models John Wiley & Sons, Inc.. pp. 576- 599 ,(2003) , 10.1002/0471249688.CH14
Jerry R. Nedelman, Ekaterina Gibiansky, David T. W. Lau, Applying Bailer's method for AUC confidence intervals to sparse sampling Pharmaceutical Research. ,vol. 12, pp. 124- 128 ,(1995) , 10.1023/A:1016255124336
Papahadjopoulos D, Szoka F, Mayhew E, Rustum Ym, Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. Cancer treatment reports. ,vol. 63, pp. 1923- ,(1979)
Franco M. Muggia, Howard A. Burris, Clinical Development of Topoisomerase-Interactive Drugs Advances in pharmacology. ,vol. 29, pp. 1- 31 ,(1994) , 10.1016/S1054-3589(08)61129-1
Franco M. Muggia, Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. ,vol. 54, pp. 22- 29 ,(1997) , 10.2165/00003495-199700544-00006
Y H Hsiang, R Hertzberg, S Hecht, L F Liu, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry. ,vol. 260, pp. 14873- 14878 ,(1985) , 10.1016/S0021-9258(17)38654-4
Jeffrey G Supko, Rocio Garcia-Carbonero, Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clinical Cancer Research. ,vol. 8, pp. 641- 661 ,(2002)
Pollack If, Erff M, Curran Dp, Bom D, Strode Jt, Burke Tg, Potent Topoisomerase I Inhibition by Novel Silatecans Eliminates Glioma Proliferation in Vitro and in Vivo Cancer Research. ,vol. 59, pp. 4898- 4905 ,(1999)
Edward K. Russell, Bruce E. Johnson, Adi F. Gazdar, Mark S. Georgiadis, Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clinical Cancer Research. ,vol. 3, pp. 449- 454 ,(1997)
B. J. Tromberg, T. B. Krasieva, E. A. Forssen, R. Malé-Brune, M. J. A. Lee, P. G. Schmidt, S. Shimizu, J. P. Adler-Moore, Fluorescence Imaging Studies for the Disposition of Daunorubicin Liposomes (DaunoXome) within Tumor Tissue Cancer Research. ,vol. 56, pp. 2066- 2075 ,(1996)